Page 9

D - Bladder Continence

REPORT CARD: Bladder Continence KNOWLEDGE GENERATION Innovaon/Discovery Integrave Care Environmental Shi Emerging Evidence Outcome Measures Resource Capacity Take Home Mesage: Ensuring systematic follow up and surveillance of individuals with SCI, in order to capture urologic problems prior to the onset of renal dysfunction/failure, is essential; and an important policy priority that needs to be incorporated into future Accreditation Standards. Funding of newer devices, medical and surgical therapies including hydrophilic catheters, M3 receptor antagonists, intravesicular botulinum toxin and continent stomas, are a priority. Resources CLINICAL APPLICATION Effecve Pracce (Evidence and Outcomes) Equity Pracce Capacity 2020 PRIORITY 3 2020 PRIORITY 2 2020 PRIORITY 1 1. Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2004;21:1371-83. 2. Herschorn S, Gajewski J, Ethans K, et al. Efficacy of Botulinum Toxin A injection for neurogenic detrusor over activity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229-35. POLICY CHANGE Change Agents Societal Awareness Community Capacity 3. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled six-month study. J Urol. 2005;174(1):196-200. 4. Mehta S, Hill D, Foley N, et al. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding following spinal cord injury. Arch Phys Med Rehabil. 2012;93(4):597-603. 60 CAPTURING CAPACITY IN CANADIAN SCI REHABILITATION


D - Bladder Continence
To see the actual publication please follow the link above